MSB 2022 - The road to commercialisation, page-1027

we’ve had some delays, and been told some reasons for them. market doesn’t like delays, nor do they like class actions. Higher global interest rates do not help growth stocks, so it’s been a bit of a tough ride recently for the share price, but the key milestones are still out there and will come into play when ready.

CLBP panel this morning gave a reminder to what these therapies can offer and answered some questions like why HA is not used in controls (because it’s an exploratory agent that is not approved for CLBP), which many have tried to elude to as poor trial design. Which of course is not the case, but some here think they know better.

strategic partners in play for CLBP and alternative funding structures can be put in place where royalties are paid to financial institutions. But realistically they will get a partner, because IMO the value in a partner is more than the funding they provide, it’s the distribution channel that holds the value.

Some investors who cry out for guidance need to read the fine print and understand HC is not for financial advice. Discussions here may form part of your own DD, but it should not be your main source of DD when investing.

goodluck all